Latest Commercial Expansion News

Artrya has launched its AI-powered Salix Coronary Anatomy platform in the U.S. and submitted its Coronary Plaque module for FDA clearance, marking a key step in its commercial expansion. A new five-year contract with Tanner Health signals the start of U.S. revenues.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

InteliCare Holdings has raised $1 million through a structured financing deal to extend its cash runway and scale its AI-driven healthcare platform across aged care and disability sectors.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Sprintex secures a key deposit from Mest Water to develop new compressors for mobile manure processing systems, leveraging a Dutch government subsidy aimed at thousands of small farms.

xReality Group has raised $2 million through a discounted share placement to fuel the international expansion of its Operator XR virtual reality training platform, targeting law enforcement and military sectors.

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.